Zetia, fenofibrate combo OK'd for cholesterol lowering

Article

Merck/Schering-Plough Pharmaceuticals has announced the approval of a new indication for Zetia (ezetimibe). The drug can now be used in combination with fenofibrate, along with diet, for the reduction of high total cholesterol and LDL cholesterol in patients with mixed hyperlipidemia, a metabolic disorder consisting of high LDL cholesterol, low HDL cholesterol, and elevated triglycerides.

Zetia, fenofibrate combo OK'd for cholesterol lowering

Merck/Schering-Plough Pharmaceuticals has announced the approval of a new indication for Zetia (ezetimibe). The drug can now be used in combination with fenofibrate, along with diet, for the reduction of high total cholesterol and LDL cholesterol in patients with mixed hyperlipidemia, a metabolic disorder consisting of high LDL cholesterol, low HDL cholesterol, and elevated triglycerides. Approval was based on a 12-week study that showed that coadministration of the two drugs led to a 20% reduction in LDL cholesterol levels compared with a 6% and 13% reduction with fenofibrate and ezetimibe as monotherapy, respectively.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.